PSMA Ligands for PET Imaging of Prostate Cancer

Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-labeled PET agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world because of the results of multiple, primarily retrospective, studies that indicate superior detection efficacy compared with standard-of-care imaging. For high-risk primary prostate cancer, evidence is growing that this modality significantly aids in the detection of otherwise occult nodal and bone metastases. For both clinical indications in recurrent as well as in primary prostate cancer, preliminary data demonstrate a substantial impact on clinical management. Emerging data imply that intraprostatic tumor localization, therapy stratification, and treatment monitoring of advanced disease in specific clinical situations might become future indications. Current criteria for image reporting of PSMA ligand PET are evolving given the expanding body of literature on physiologic and pathologic uptake patterns and pitfalls. This article intends to give an educational overview on the current status of PSMA ligand PET imaging, including imaging procedure and interpretation, clinical indications, diagnostic potential, and impact on treatment planning.

[1]  J. Pruim,et al.  18F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution , 2017, The Journal of Nuclear Medicine.

[2]  R. Velthoven,et al.  Clinical impact of 68Ga‐prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate‐specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach , 2017, BJU international.

[3]  K. Schwamborn,et al.  Value of 111In‐prostate‐specific membrane antigen (PSMA)‐radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow‐up , 2017, BJU international.

[4]  A. Drzezga,et al.  PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[5]  R. Mansberg,et al.  Incidental PSMA Uptake in an Undisplaced Fracture of a Vertebral Body. , 2017, Clinical nuclear medicine.

[6]  N. Lawrentschuk,et al.  Utility of 68Ga prostate specific membrane antigen – positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma , 2017, Journal of medical imaging and radiation oncology.

[7]  H. Kauczor,et al.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Funda Aydın,et al.  68Ga-PSMA Uptake by Dermatofibroma in a Patient With Prostate Cancer. , 2017, Clinical nuclear medicine.

[9]  T. Holland-Letz,et al.  The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[10]  Thomas A. Hope,et al.  Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT. , 2017, Clinical nuclear medicine.

[11]  M. Vendelbo,et al.  Subcutaneous Lobular Capillary Hemangioma on 68Ga-PSMA PET/CT. , 2017, Clinical nuclear medicine.

[12]  Johan De Mey,et al.  PSMA Uptake in Mediastinal Sarcoidosis. , 2017, Clinical nuclear medicine.

[13]  Bernd J. Krause,et al.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  T. Derlin,et al.  Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  S. K. Singh,et al.  Incidental detection of tracer avidity in meningioma in 68Ga-PSMA PET/CT during initial staging for prostate cancer. , 2017, Revista espanola de medicina nuclear e imagen molecular.

[16]  M. Wirth,et al.  Prostate-specific Membrane Antigen-targeted Ligand Positron Emission Tomography/Computed Tomography and Immunohistochemical Findings in a Patient With Synchronous Metastatic Penile and Prostate Cancer. , 2017, Urology.

[17]  U. Haberkorn,et al.  Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence. , 2017, Clinical nuclear medicine.

[18]  T. Derlin,et al.  PSMA Expression in Tumor Neovasculature Endothelial Cells of Follicular Thyroid Adenoma as Identified by Molecular Imaging Using 68Ga-PSMA Ligand PET/CT. , 2017, Clinical nuclear medicine.

[19]  B. Buerke,et al.  Gastrointestinal Stromal Tumor Showing Intense Tracer Uptake on PSMA PET/CT. , 2017, Clinical nuclear medicine.

[20]  C. Jilg,et al.  Strong PSMA Radioligand Uptake by Rectal Carcinoma: Who Put the "S" in PSMA? , 2017, Clinical nuclear medicine.

[21]  A. Rezaee,et al.  68Ga-PSMA-HBED Uptake on Cervicothoracic (Stellate) Ganglia, a Common Pitfall on PET/CT. , 2017, Clinical nuclear medicine.

[22]  K. Bouchelouche,et al.  Prostate-Specific Membrane Antigen PET/CT: Uptake in Lymph Nodes With Active Sarcoidosis. , 2017, Clinical nuclear medicine.

[23]  E. Hsiao,et al.  Subacute Cortical Infarct Showing Uptake on 68Ga-PSMA PET/CT. , 2017, Clinical nuclear medicine.

[24]  A. Sasikumar,et al.  68Ga-PSMA PET/CT Imaging in Multiple Myeloma. , 2017, Clinical nuclear medicine.

[25]  P. Thomas,et al.  Intense Uptake in Amyloidosis of the Seminal Vesicles on 68Ga-PSMA PET Mimicking Locally Advanced Prostate Cancer. , 2017, Clinical nuclear medicine.

[26]  M. Schwaiger,et al.  Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[27]  M. Bock,et al.  Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology , 2017, Theranostics.

[28]  Steven P Rowe,et al.  PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy. , 2017, European urology.

[29]  A. Jena,et al.  68Ga-PSMA Uptake in Hepatocellular Carcinoma. , 2017, Clinical nuclear medicine.

[30]  S. Singh,et al.  68Ga-PSMA Expression in Pseudoangiomatous Stromal Hyperplasia of the Breast. , 2017, Clinical nuclear medicine.

[31]  G. Schembri,et al.  Serous Cystadenoma of the Pancreas Showing Uptake on 68Ga PSMA PET/CT. , 2017, Clinical nuclear medicine.

[32]  M. Aras,et al.  A potential pitfall in the use of 68Ga-PSMA PET/CT: Anthracosis. , 2017, Revista espanola de medicina nuclear e imagen molecular.

[33]  T. Poeppel,et al.  Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT , 2017, Clinical nuclear medicine.

[34]  Damien Bolton,et al.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[35]  P. Thomas,et al.  Prostate-Specific Membrane Antigen PET/CT Findings for Hepatic Hemangioma. , 2016, Clinical nuclear medicine.

[36]  T. Çermik,et al.  Incidental Meningioma Mimicking Metastasis of Prostate Adenocarcinoma in 68Ga-Labeled PSMA Ligand PET/CT. , 2016, Clinical nuclear medicine.

[37]  B. Hadaschik,et al.  F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  A. Maes,et al.  68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  M. Schwaiger,et al.  Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. , 2016, European urology.

[40]  H. Everaert,et al.  Aspecific Uptake of 68GA-PSMA in Paget Disease of the Bone. , 2016, Clinical nuclear medicine.

[41]  A. Buck,et al.  Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy , 2016, EJNMMI Research.

[42]  J. Preston,et al.  Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour , 2016, EJNMMI Research.

[43]  A. Drzezga,et al.  Prostate-Specific Membrane Antigen–Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[44]  C. Stief,et al.  68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. , 2016, European urology.

[45]  K. Rahbar,et al.  Subacute Stroke Mimicking Cerebral Metastasis in 68Ga-PSMA-HBED-CC PET/CT. , 2016, Clinical nuclear medicine.

[46]  Chuong Bui,et al.  Prostate-Specific Membrane Antigen (PSMA) Avid Pancreatic Neuroendocrine Tumor. , 2016, Clinical nuclear medicine.

[47]  A. Sasikumar,et al.  68Ga-PSMA PET/CT False-Positive Tracer Uptake in Paget Disease. , 2016, Clinical nuclear medicine.

[48]  T. Maurer,et al.  68Ga-PSMA PET/MR Showing Intense PSMA Uptake in Nodular Fasciitis Mimicking Prostate Cancer Metastasis. , 2016, Clinical nuclear medicine.

[49]  U. Haberkorn,et al.  The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[50]  J. Yaxley,et al.  The use of 68 Ga‐PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer , 2016, BJU international.

[51]  Sait Sağer,et al.  Incidental Detection of Follicular Thyroid Carcinoma in 68Ga-PSMA PET/CT Imaging , 2016, The Journal of Nuclear Medicine Technology.

[52]  P. Thomas,et al.  Paget Disease: A Potential Pitfall in PSMA PET for Prostate Cancer. , 2016, Clinical nuclear medicine.

[53]  M. Essler,et al.  68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer. , 2016, Clinical nuclear medicine.

[54]  G. Schembri,et al.  Schwannoma Showing Avid Uptake on 68Ga-PSMA-HBED-CC PET/CT. , 2016, Clinical nuclear medicine.

[55]  C. Nanni,et al.  PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  R. Hermann,et al.  Prostate-Specific Membrane Antigen PET/CT: False-Positive Results due to Sarcoidosis? , 2016, Case Reports in Oncology.

[57]  M. Schwaiger,et al.  Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. , 2016, The Journal of urology.

[58]  K. Miles,et al.  Gallium‐68 PSMA uptake in adrenal adenoma , 2016, Journal of medical imaging and radiation oncology.

[59]  Lode Goethals,et al.  Healing Sacral Fracture Masquerading as Metastatic Bone Disease on a 68Ga-PSMA PET/CT. , 2016, Clinical nuclear medicine.

[60]  Manoj Gupta,et al.  Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy , 2016, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.

[61]  Baris Turkbey,et al.  Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer , 2016, CA: a cancer journal for clinicians.

[62]  M. Schwaiger,et al.  Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[63]  M. Schwaiger,et al.  Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[64]  M. Schwaiger,et al.  68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report , 2016, Cancer Imaging.

[65]  C. Stief,et al.  68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[66]  M. Schwaiger,et al.  Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy , 2016, The Journal of Nuclear Medicine.

[67]  A. Kneebone,et al.  Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT. , 2016, Clinical nuclear medicine.

[68]  T. Poeppel,et al.  In Vivo Visualization of Prostate-Specific Membrane Antigen in Adenoid Cystic Carcinoma of the Salivary Gland. , 2016, Clinical nuclear medicine.

[69]  T. Eade,et al.  Desmoid Tumor Showing Intense Uptake on 68Ga PSMA-HBED-CC PET/CT. , 2016, Clinical nuclear medicine.

[70]  M. Schwaiger,et al.  Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study , 2016, Radiation Oncology.

[71]  P. Stricker,et al.  68Ga‐PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment , 2016, BJU international.

[72]  H. Loh,et al.  Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer. , 2016, Clinical nuclear medicine.

[73]  M. Schwaiger,et al.  68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases. , 2016, Clinical nuclear medicine.

[74]  C. Bal,et al.  PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer? , 2016, Clinical nuclear medicine.

[75]  Steve Y. Cho,et al.  PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer , 2016, Molecular Imaging and Biology.

[76]  K. Rahbar,et al.  Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[77]  G. Schembri,et al.  Follicular Thyroid Adenoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT. , 2016, Clinical nuclear medicine.

[78]  I. Steffen,et al.  Biodistribution of [68Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions , 2016, Molecular Imaging and Biology.

[79]  R. Kumar,et al.  Unusual Uptake of Prostate Specific Tracer 68Ga-PSMA–HBED-CC in a Benign Thyroid Nodule , 2016, Nuclear Medicine and Molecular Imaging.

[80]  R. Knuechel,et al.  Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[81]  Shyam Natarajan,et al.  Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: The role of systematic and targeted biopsies , 2016, Cancer.

[82]  Kristina Schwamborn,et al.  68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[83]  P. Thomas,et al.  Rectal Carcinoma on 68Ga-PSMA PET/CT. , 2016, Clinical nuclear medicine.

[84]  H. Heinzer,et al.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. , 2016, European urology.

[85]  R. Fimmers,et al.  Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer , 2016, Oncotarget.

[86]  R. Baum,et al.  177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy , 2016, The Journal of Nuclear Medicine.

[87]  Steve Y. Cho,et al.  Comparison of Prostate-Specific Membrane Antigen–Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[88]  M. Javadi,et al.  Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma. , 2016, Clinical nuclear medicine.

[89]  G. Antoch,et al.  Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[90]  K. Nikolaou,et al.  Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[91]  C. Ritter,et al.  Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[92]  Ahmedin Jemal,et al.  Global Cancer Incidence and Mortality Rates and Trends—An Update , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[93]  C. Ritter,et al.  Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga‐PSMA‐positron emission tomography/computerized tomography , 2015, The Prostate.

[94]  Steve Y. Cho,et al.  Uptake of [18F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies , 2015, Tomography.

[95]  T. Shakespeare Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists , 2015, Radiation Oncology.

[96]  L. Trojan,et al.  Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy , 2015, EJNMMI Research.

[97]  D. Maintz,et al.  Prostate-Specific Membrane Antigen PET/CT in Splenic Sarcoidosis. , 2015, Clinical nuclear medicine.

[98]  Tim Holland-Letz,et al.  The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions , 2015, The Journal of Nuclear Medicine.

[99]  U. Haberkorn,et al.  68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[100]  Nassir Navab,et al.  Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. , 2015, European urology.

[101]  Zsolt Szabo,et al.  Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT , 2015, Annals of Nuclear Medicine.

[102]  C. Nanni,et al.  18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT , 2015, Clinical nuclear medicine.

[103]  S. Fanti,et al.  Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.

[104]  Michael Lassmann,et al.  68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies , 2015, The Journal of Nuclear Medicine.

[105]  Toby C. Cornish,et al.  18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[106]  A. Drzezga,et al.  Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer , 2015, Molecular Imaging and Biology.

[107]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[108]  F. Mottaghy,et al.  First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[109]  M. Schwaiger,et al.  Intense PSMA-expression using 68Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[110]  W. Oyen,et al.  PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[111]  R. Velthoven,et al.  Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[112]  F. Mottaghy,et al.  [68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[113]  Ximing J. Yang,et al.  Neuroendocrine differentiation of prostate cancer: a review. , 2014, American journal of clinical and experimental urology.

[114]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[115]  V. Ambrosini,et al.  18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. , 2014, Clinical genitourinary cancer.

[116]  G. Tabatabai,et al.  In vivo visualization of prostate-specific membrane antigen in glioblastoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[117]  T. Holland-Letz,et al.  Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[118]  P. Muzzio,et al.  Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. , 2013, European urology.

[119]  V. Ambrosini,et al.  Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[120]  H. Jadvar Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[121]  H. Zaidi,et al.  First imaging results of an intraindividual comparison of 11C-acetate and 18F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[122]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[123]  George Sgouros,et al.  Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[124]  Tiancheng Liu,et al.  Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells , 2012, International journal of oncology.

[125]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[126]  W. Eckelman,et al.  123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy , 2011, The Journal of Nuclear Medicine.

[127]  M. Schwaiger,et al.  The Sensitivity of [11C]Choline PET/CT to Localize Prostate Cancer Depends on the Tumor Configuration , 2011, Clinical Cancer Research.

[128]  Slave Trajanoski,et al.  Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.

[129]  Anke M Hövels,et al.  MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. , 2008, The Lancet. Oncology.

[130]  E. Adang,et al.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.

[131]  Ming-Fong Lin,et al.  Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. , 2007, Endocrine-related cancer.

[132]  N. Bander Technology Insight: monoclonal antibody imaging of prostate cancer , 2006, Nature Clinical Practice Urology.

[133]  S. Larson,et al.  2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy , 2005, Clinical Cancer Research.

[134]  Adilson Prando,et al.  Baseline staging of newly diagnosed prostate cancer: a summary of the literature. , 2004, International braz j urol : official journal of the Brazilian Society of Urology.

[135]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[136]  Sam S. Chang Overview of prostate-specific membrane antigen. , 2004, Reviews in urology.

[137]  J. Parsons,et al.  Degradation of halogenated aromatic compounds , 2004, Biodegradation.

[138]  J. Bowie,et al.  A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. , 2003, Molecular biology of the cell.

[139]  D. Bostwick,et al.  Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma , 1998, Cancer.

[140]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[141]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[142]  George L. Wright,et al.  Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.

[143]  G. Murphy,et al.  Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. , 1995, Anticancer research.